CRISPR-Cas9 can cure sickle cell disease, yet 80% of patients with this condition—most of whom live in sub-Saharan Africa—will never access this therapy. Therapeutic success without equitable access and robust governance represents a new form of health inequity rather than medical triumph. This review examines the progression of genome editing from laboratory tool to approved therapy, analyzes why current delivery and manufacturing models limit global access, and evaluates governance frameworks required before germline editing becomes technically inevitable. Clinical trials report notable efficacy: exagamglogene autotemcel achieved 94% vaso-occlusive crisis-free survival and 89% transfusion independence. However, significant barriers persist: off-target effects, delivery limitations, manufacturing costs exceeding $2.2 million per treatment, and fragmented international governance. The path forward requires reconceptualizing who benefits from biomedical innovation—not as an afterthought
